• Correlate relationships between deficiency disorders and specific genetic mutations.
• Identify the types of primary immunodeficiency disorders most commonly encountered by clinical immunologists.
• List characteristics of common variable immunodeficiency (CVID).
• Identify the most common infective manifestation of the antibody deficiencies found in the common variable immunodeficiency syndromes.
• Recognize the observations that support the concept that defective immunoregulation is contributing to poor B-cell function in patients with CVID.
• Specify the medical management of patients with CVID.
• Identify the genetic mutation that causes X-linked agammaglobulinemia (XLA).
• List the cardinal immunological features of XLA.
• Identify characteristic findings of severe combined immunodeficiency (SCID) disorders.
• List microorganisms that are predominantly responsible for recurrent infections in patients with SCID disorders.
• Identify precautions that must be taken with babies with SCID disorders.
• Identify the main curative option for children with SCID.
• Identify the findings in patients which would trigger investigation of suspected immunodeficiency among other tests in a differential diagnosis.   
• Identify specific pathogens involved in infections which provide clues as to which components of the immune system may be defective.    

Management of Immunodeficiency 

• List autoimmune diseases for which IV immunoglobulin (IvIg) is considered the treatment of choice, as evidenced from randomized controlled trials.
• Identify conditions under which patients may develop an anaphylactic reaction on exposure to IvIg preparations.
• Recognize the practices that have minimized IvIg-associated acute hemolysis due to passive transmission of anti-blood groups antibodies to patients from IvIg infusions.
• Identify the substance in IvIg preparations responsible for the nephrotoxicity that may occur in patients with preexisting diabetes and renal disease who are infused with these preparations.
• Indicate the reasons that IvIg therapy should be avoided or used with caution in patients with mixed cryoglobulinemia.
• Identify the virus that may still be transmitted via IVIg infusions despite strict donor screening and additional antiviral steps during plasma fractionation.